Triomics nabs $22M to bring oncology-specific AI to cancer centers
Triomics raised $22 million to expand its oncology AI platform for clinical-trial matching, chart summaries, and admin tasks at cancer centers.
Intelligence analysis by GPT-5.4 Mini
Triomics closed a $22 million Series B to push its oncology-specific AI deeper into cancer centers. The startup says its models are tuned for cancer workflows, where dense records and paperwork create major bottlenecks.
Cancer doctors and hospital staff have to read piles of papers, scans, and notes for each patient. Triomics makes a computer helper that sorts through that mountain and pulls out the important parts.
It also helps find which patients might fit a clinical trial, like matching puzzle pieces. That can save time before appointments and cut down on boring paperwork.
Think of it like a super-fast librarian for cancer records. Instead of hunting through thousands of pages, the team gets a short, useful summary right away.
Analysis
What Triomics does
Triomics builds an AI-powered platform for oncology teams. Its software helps automate data-heavy work such as matching patients to clinical trials, preparing for appointments, summarizing charts, and submitting tumor reports to government registries, which cancer centers are legally required to do.
Why the company says it matters
The company’s pitch is rooted in how complicated cancer records can be. Oncology patients often have years of notes, scans, pathology reports, and other documents that staff must review before visits or research enrollment. Triomics says its summaries are meant to appear inside the clinical tools doctors already use, reducing the need to switch between systems. That is especially relevant in oncology, where long histories and staff burnout make administrative load a serious problem.
The funding and traction
Triomics raised a $22 million Series B led by Battery Ventures. Returning investors included Nexus Venture Partners, Lightspeed, Y Combinator, and others. The startup was founded in 2021 and previously raised a $15 million Series A in mid-2024.
Positioning and competition
According to co-founder Sarim Khan, institutions such as Memorial Sloan Kettering and Yale Cancer Center use Triomics because its models are trained on oncology data rather than generic medical text. In chart summarization, the company faces competition from AI medical scribe products like Abridge and Microsoft’s Nuance. Triomics says it has grown quickly anyway, with its enterprise customer base up fourfold over the past year and annualized recurring revenue up 10-fold.
Key points
- Triomics raised $22 million in Series B funding led by Battery Ventures.
- The startup focuses on oncology workflows, including trial matching, chart summaries, and registry reporting.
- It says its AI is trained on oncology data and is used by institutions including Memorial Sloan Kettering and Yale Cancer Center.
- The company says its enterprise customer base grew fourfold in the past year and annualized recurring revenue rose 10-fold.
